Durability of response to immune checkpoint inhibitors in metastatic Merkel cell carcinoma after treatment cessation-Reference-Cited by-同舟云学术

Durability of response to immune checkpoint inhibitors in metastatic Merkel cell carcinoma after treatment cessation

Published:2023-04 Issue: Volume:183 Page:109-118
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Weppler Alison M.^ORCID,Da Meda Laetitia,Pires da Silva Ines,Xu Wen,Grignani Giovanni,Menzies Alexander M.,Carlino Matteo S.,Long Georgina V.^ORCID,Lo Serigne N.^ORCID,Nordman Ina,Steer Christopher B.^ORCID,Lyle Megan,Trojaniello Claudia,Ascierto Paolo A.^ORCID,Lebbe Celeste^ORCID,Sandhu Shahneen

Funder

Roche

EMD Serono

Bristol-Myers Squibb

Bayer

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference24 articles.

1. Analysis of prognostic factors from 9387 merkel cell carcinoma cases forms the basis for the new 8th edition AJCC staging system;Harms;Ann Surg Oncol,2016

2. First-line avelumab in a cohort of 116 patients with metastatic Merkel cell carcinoma (JAVELIN Merkel 200): primary and biomarker analyses of a phase II study;D'Angelo;J Immunother Cancer,2021